← IndicationsOpen filtered programs
Landscape
Meniere Disease
Meniere Disease has 4 tracked records across 3 named organizations, including 0 strong-evidence records and 2 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
4
Pipeline Records
strong evidence + caveats + candidates
0
Strong Evidence
4 checked records with caveats
2
Active Programs
currently active
0
Marketed / Approved
commercial or approved
3
Organizations
companies, sponsors, and institutions
Competitive Density
9/100
organization breadth + program volume
Pipeline Velocity
58/100
active and late-stage share
Evidence Coverage
0/100
share strong evidence
Completion Signal
75/100
late-stage, approved, or marketed
Attrition Rate
25/100
share discontinued
Concentration
50/100
top-organization share
Programs by Stage
Phase 1/21 · 25%
Phase 32 · 50%
Phase 41 · 25%
Trial / Program Status
Active2 · 50%
Completed1 · 25%
Discontinued1 · 25%
Modality Breakdown
Steroid/Anti-inflammatory2 · 50%
Drug Delivery1 · 25%
Small Molecule1 · 25%
Program Types
Therapeutic4 · 100%
Top Organizations
Institution-led study2 · 50%
Institution-led study cluster1 · 25%
Otonomy1 · 25%
Population Tags
adult4 · 100%
meniere-disease3 · 75%
drug-delivery1 · 25%
hearing-loss1 · 25%
ototoxicity-risk1 · 25%
pediatric1 · 25%
sensorineural1 · 25%
study-cluster1 · 25%
study-level1 · 25%
sudden1 · 25%
Strong-Evidence Programs
0 recordsNo strong-evidence records yet for this indication.
Checked Records With Caveats
4 recordsOTO-104 (dexamethasone) by Otonomy
Company: Otonomy · Phase 3 · Discontinued
Steroid/Anti-inflammatoryPhase 3Discontinued90% confidence
Leiden PREDMEN intratympanic methylprednisolone Meniere disease studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 3 · Active
Steroid/Anti-inflammatoryPhase 3Active86% confidence
Montelukast Hearing and Vestibular Study ClusterStatus caveat
Sponsor / Institution: Institution-led study cluster · Phase 4 · Active
Small MoleculePhase 4Active78% confidence
SNUH dexamethasone/hyaluronic-acid intratympanic delivery studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1/2 · Completed
Drug DeliveryPhase 1/2Completed76% confidence